The American Journal of Managed Care6d
ESA Treatment Improves OS in Lower-Risk MDS
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival ...
Medscape3mon
Dendritic Cells in Myelodysplastic Syndromes
The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...
CURE9d
EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...
The American Journal of Managed Care8d
ELN Scoring System Shows Similar Accuracy to iFS for MDS Diagnosis
The European LeukemiaNet (ELN) scoring system showed similar results to the more complicated Integrated Flow Score (iFS) for ...
Hosted on MSN1y
EC approves Bristol Myers Squibb’s Reblozyl for first-line MDS treatment
low and intermediate-risk myelodysplastic syndromes (MDS). The decision is applicable in all the member states of the European Union (EU). The EC’s expanded approval is based on the results from ...
pharmaphorum3d
BMS announces positive Reblozyl phase 3 results for MDS
MDS are a group of closely related blood cancers ... However, frequent transfusions are associated with an increased risk of iron overload, transfusion reactions, and infections in themselves.